Gene therapies show benefit in X-linked retinoschisis, Leber congenital amaurosis

DENVER — Two studies presented at the Association for Research in Vision and Ophthalmology meeting explored the benefits of ATSN-101 for Leber congenital amaurosis and ATSN-201 for X-linked retinoschisis. In July, Atsena Therapeutics received orphan drug designation for the two gene therapy candidates from the European Medicines Agency, according to a press release.